WHAT IS CLAIMED IS:

1. A pharmaceutical composition, comprising:

a pharmaceutically acceptable carrier; and

a silver-containing material in the pharmaceutically acceptable carrier,

wherein the pharmaceutical composition comprises from about 0.001 weight percent to about 50 weight percent of the silver-containing material.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about 0.1 weight percent of the silver-containing material.

3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about 0.5 weight percent of the silver-containing material.

4. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises less than about 40 weight percent of the silver-containing material.

5. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises less than about 30 weight percent of the silver-containing material.

6. The pharmaceutical composition of claim 1, wherein the silver-containing material is selected from the group consisting of colloidal silver, silver nitrate and silver sulfadiazine, silver carbonate, silver acetate, silver lactate, silver citrate, silver oxide, silver hydroxide, silver succinate, silver chlorate, alkali silver thiosulphates, silver myristate, silver sorbate, silver stearate, silver oleate, silver glutonate, silver adipate, atomically disordered silver, nanocrystalline silver and combinations thereof.

7. A method of treating a subject having a condition, comprising:

contacting an area of the subject having the condition with a pharmaceutical composition, the pharmaceutical composition comprising:

a pharmaceutically acceptable carrier; and

a silver-containing material in the pharmaceutically acceptable carrier,

wherein the pharmaceutical composition comprises from about 0.001 weight percent to about 50 weight percent of the silver-containing material.

8. The method of claim 7, wherein the pharmaceutical composition comprises at least about 0.1 weight percent of the silver-containing material.

9. The method of claim 7, wherein the pharmaceutical composition comprises at least about 0.5 weight percent of the silver-containing material.

10. The method of claim 7, wherein the pharmaceutical composition comprises less than about 40 weight percent of the silver-containing material.

11. The method of claim 7, wherein the pharmaceutical composition comprises less than about 30 weight percent of the silver-containing material.

12. The method of claim 7, wherein the silver-containing material is selected from the group consisting of colloidal silver, silver nitrate and silver sulfadiazine, silver carbonate, silver acetate, silver lactate, silver citrate, silver oxide, silver hydroxide, silver succinate, silver chlorate, alkali silver thiosulphates, silver myristate, silver sorbate, silver stearate, silver oleate, silver glutonate, silver adipate, atomically disordered silver, nanocrystalline silver and combinations thereof.

13. The method of claim 7, bacterial conditions, biofilm conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, hyperproliferative conditions, noncancerous growths and cancerous conditions.

14. The method of claim 7, wherein the condition comprises a skin condition.

15. A method of treating a subject having a respiratory condition, comprising:

contacting an area of the subject having the respiratory condition with a silver-containing material.

16. The method of claim 15, wherein the respiratory condition is selected from the group consisting of bacterial conditions, biofilm conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths, hyperproliferative conditions, cancerous conditions and combinations thereof.

17. The method of claim 15, wherein the condition is selected from the group consisting of asthma, emphysema, bronchitis, pulmonary edema, acute respiratory distress syndrome, bronchopulmonary dysplasia, fibrotic conditions, pulmonary atelectasis, tuberculosis, pneumonia, sinusitis, allergic rhinitis, pharyngitis, mucositis, stomatitis, chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis and combinations thereof.

18. The method of claim 15, wherein the silver-containing material is selected from the group consisting of colloidal silver, silver nitrate and silver sulfadiazine, silver carbonate, silver acetate, silver lactate, silver citrate, silver oxide, silver hydroxide, silver succinate, silver chlorate, alkali silver thiosulphates, silver myristate, silver sorbate, silver stearate, silver oleate, silver glutonate, silver adipate, atomically disordered silver, nanocrystalline silver and combinations thereof.

19. The method of claim 15, wherein, when contacted with the area of the subject having the respiratory condition, the silver-containing material is in a solution, in an aerosol, in a pharmaceutically acceptable carrier, or in the form of a free-standing powder.

20. The method of claim 15, wherein the area of the subject is selected from the group consisting of the subject's oral cavity, the subject's nasal cavity, the subject's lungs and combinations thereof.

21. The method of claim 15, wherein, when contacted with the area of the subject having the respiratory condition, the silver-containing material is in a solution, and the solution contains at most about 0.5 weight percent of the silver-containing material.

22. The method of claim 15, wherein, when contacted with the area of the subject having the respiratory condition, the silver-containing material is the form of a dry powder aerosol, and the dry powder aerosol contains at most about 99 weight percent of the silver-containing material.

23. The method of claim 22, wherein the dry powder aerosol contains at least about 10 weight percent of the silver-containing material.

24. A method of treating a subject having a condition, comprising:

contacting an area of the subject having the condition with a silver-containing material by injecting a free-standing powder of the silver-containing material into the subject, or by inhaling a free-standing powder of the silver-containing material,

wherein the silver-containing material is selected from the group consisting of colloidal silver, silver nitrate and silver sulfadiazine, silver carbonate, silver acetate, silver lactate, silver citrate, silver oxide, silver hydroxide, silver succinate, silver chlorate, alkali silver thiosulphates, silver myristate, silver sorbate, silver stearate, silver oleate, silver glutonate, silver adipate, atomically disordered silver, nanocrystalline silver and combinations thereof.

25. The method of claim 24, wherein the condition is selected from the group consisting of wherein the condition is selected from the group consisting of bacterial conditions, biofilm conditions, microbial conditions, inflammatory conditions, fungal

conditions, viral conditions, autoimmune conditions, idiopathic conditions, hyperproliferative conditions, noncancerous growths, cancerous conditions and combinations thereof.

26. The method of claim 24, wherein the condition is selected from skin conditions, integument conditions, respiratory conditions, musculo-skeletal conditions, circulatory conditions, mucosal conditions, serosal conditions and combinations thereof.

27. The method of claim 24, wherein the free-standing powder has an average particle size of about 10 microns or less.

28. A free-standing powder of a silver-containing material,

wherein the silver-containing material is selected from the group consisting of colloidal silver, silver nitrate and silver sulfadiazine, silver carbonate, silver acetate, silver lactate, silver citrate, silver oxide, silver hydroxide, silver succinate, silver chlorate, alkali silver thiosulphates, silver myristate, silver sorbate, silver stearate, silver oleate, silver glutonate, silver adipate, atomically disordered silver, nanocrystalline silver and combinations thereof.

29. The method of claim 28, wherein the free-standing powder has an average particle size of about 10 microns or less.

30. An aerosol comprising a silver-containing material, wherein the silver-containing material is selected from the group consisting of colloidal silver, silver nitrate and silver sulfadiazine, silver carbonate, silver acetate, silver lactate, silver citrate, silver oxide, silver hydroxide, silver succinate, silver chlorate, alkali silver thiosulphates, silver myristate, silver sorbate, silver stearate, silver oleate, silver glutonate, silver adipate, atomically disordered silver, nanocrystalline silver and combinations thereof.

31. The aerosol of claim 30, wherein the aerosol further comprises a solvent for the silver-containing material.

32. The aerosol of claim 31, wherein the aerosol comprises at most about 99 weight percent of the silver-containing material.

33. The aerosol of claim 30, wherein the aerosol comprises at most about 99 weight percent of the silver-containing material.